DOCSLIB.ORG

2016 Tbilisi

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2016 Tbilisi NATIONAL INTELLECTUAL PROPERTY CENTER OF GEORGIA SAKPATENTI 20(456) 2016 TBILISI INID CODES FOR IDENTIFICATION OF BIBLIOGRAPHIC DATA LIST OF CODES, IN ALPHABETIC SEQUENCE, AND THE CORRESPONDING (SHORT) NAMES OF STATES, OTHER ENTITIES AND INTERGOVERNMENTAL ORGANIZATIONS (WIPO STANDARD ST.3) INVENTIONS, UTILITY MODELS (10) Number of publication for application, which has been examined (54) Title of the invention AD Andorra for the Arab States of the Gulf (GCC) NE Niger (11) Number of patent and kind of document (57) Abstract AE United Arab Emirates GD Grenada NG Nigeria (21) Serial number of application (60) Number of examined patent document granted by foreign patent office, date from which patent AF Afghanistan GG Guernsey NI Nicaragua (22) Date of filing of the application has effect and country code (62) Number of the earlier application and in case of divided application, date of filing an AG Antigua and Barbuda GH Ghana NL Netherlands (23) Date of exhibition or the date of the earlier filing and the number of application, if any application AI Anguilla GI Gibraltar NO Norway (24) Date from which patent may have effect (71) Name, surname and address of applicant (country code) AL Albania GT Guatemala NP Nepal (31) Number of priority application (72) Name, surname of inventor (country code) AM Armenia GW Guinea- Bissau NR Nauru (32) Date of filing of priority application (73) Name, surname and address of patent owner (country code) AN Netherlands Antilles GY Guyana NZ New Zealand (33) Code of the country or regional organization allotting priority application number (74) Name, surname of representative or patent attorney AO Angola HK The Hong Kong Special Administrative OA African Intellectual Property Organization (44) Date of publication of application not granted, but examined and number of bulletin (85) Date of commencement of the national phase of International Application AP African Regional Intellectual Region of the People’s Republic of China (OAPI) (45) Date of publication of registered document (86) Number and date of filing of international application Property Organization (ARIPO) HN Honduras OM Oman (51) International Patent Classification Index (87) Number and date of publication of international application AR Argentina HR Croatia PA Panama AT Austria HT Haiti PE Peru DESIGNS AU Australia HU Hungary PG Papua New Guinea AW Aruba IB International Bureau of the World PH Philippines (51) International Classification for designs (class and subclass of the Locarno (10) Number of publication for application AZ Azerbaijan Intellectual Property Organization (WIPO) PK Pakistan (11) Nnumber of patent and kind of document or number of registration Classification) (54) Title of the invention BA Bosnia and Herzegovina ID Indonesia PL Poland (15) Date of registration/Date of patent renewal BB Barbados IE Ireland PT Portugal (18) Expected expir ation date of patent or registration (55) Reproduction of the design (57) Description of characteristic features of the design including indication of colors BD Bangladesh IL Israel PW Palau (21) Serial number of application BE Belgium IM Isle of Man PY Paraguay (22) Date of filing of the application (58) Date of recording of any kind of amendment in the Register (62) Number of the earlier application, registration and document number and if available the date BF Burkina Faso IN India QA Qatar (23) Date of exhibition or the date of the earlier filing and the number of application, if any of filing an application in case of divided application BG Bulgaria IQ Iraq QZ Community Plant Variety Office (24) Date from which patent may have effect (71) Name, surname and address of applicant (country code) BH Bahrain ID Indonesia (European Community) (CPVO) (28) Number of designs included in the application (72) Name, surname of creator (country code) BI Burundi IE Ireland RO Romania (30) Data relating to priority (number of application, date of filing of application, two-letter code (73) Name, surname and address of patent owner (country code) identifying the authority with whom the priority application was made) BJ Benin IL Israel RS Serbia (31) Number of priority application (74) Name, surname of representative or patent attorney BM Bermuda IM Isle of Man RU Russian Federation (81) Contracting states concerned (32) Date of filing of priority application BN Brunei Darussalam IN India RW Rwanda II designated contracting states according to the 1960 Act BO Bolivia IQ Iraq SA Saudi Arabia (33) Code of the country or regional organization allotting priority application number III designated contracting states according to the 1999 Act (34) Two-letter code according to WIPO St.3 identifying the authority with which the priority (85) Owner’s permanent address BR Brazil IR Iran (Islamic Republic of) SB Solomon Islands application was made (86) Owner’s nationality BS Bahamas IS Iceland SC Seychelles Date of publication of design and number of bulletin (the first publication) (44) (87) Owner’s residence BT Bhutan IT Italy SD Sudan (45) Date of publication of design registered by WIPO and number of bulletin (88) State in which the owner has a real and effective industrial or commercial establishment BV Bouvet Island JE Jersey SG Singapore BW Botswana JM Jamaica SH Saint Helena TRADEMARKS BX Benelux Office for Intellectual JO Jordan SI Slovenia Property (BOIP) JP Japan SK Slovakia Description of figurative elements of Trade Marks according to the International (111) _ Number of registration (531) _ Belarus Kenya Sierra Leone Classification of the Figurative Elements of Marks BY KE SL (151) _ Date of registration BZ Belize KG Kyrgyzstan SM San Marino (156) _ Date of the renewal (540) _ Reproduction of Trade Mark (550) _ Nature and kind of Trade Mark CA Canada KH Cambodia SN Senegal (181) _ Expected expiration date of registration CD Democratic Republic of the KI Kiribati SO Somalia (186) _ Reneval expiration date of registration (580) _ Date of recording of any kind changes in respect of applications or registrations (591) _ Information concerning colors claimed Congo KM Saint Kitts and Nevis SR Suriname (141) _ Data of cancel of duration of the mark CF Central African Republic KP Democratic People’s Republic of Korea ST Sao Tome and Principe (210) _ Serial number of application (731) _ Name and address of the applicant (732) _ Name and address of the holder of the registration CG Congo KR Republic of Korea SV El Salvador (220) _ Date of filing of the application CH Switzerland KW Kuwait SY Syrian Arab Republic (230) _ Data concerning exhibition (740) _ Name and address of the representative (750) _ Adrees for correspondence CI Cote d’lvoire KY Cayman Islands SZ Swaziland (260) _ Number of application, for which favorable decision of examination about registration has CK Cook Islands KZ Kazakhstan TC Turks and Caicos Islands been taken (publication number) (770) _ Name and address of the previous applicant or holder in case of change in ownership Chad Number of the first application CL Chile LA Lao People’s Democratic Republic TD (310) _ (771) _ Previous name and address of the applicant or holder in case of change in ownership Togo Date of filing of the first application CM Cameroon LB Lebanon TG (320) _ (791) _ Name and address of the licensee Thailand Code, identifying national or regional Office where the first application was made (793) _ Indication of conditions and/or restrictions under the license (Type of license, number of CN China LC Saint Lucia TH (330) _ Tajikistan (511) _ International Classification of Goods and Services for the purposes of registration of trade license agreement, data of license, data of validity of license) CO Colombia LI Liechtenstein TJ marks and/or list of goods and/or services classified according thereto (800) _ Certain data relating to the international registration of Trade Marks under the CR Costa Rica LK Sri Lanka TL Timor-Leste Protocol Relating to Madrid Agreement (International registration number CU Cuba LR Liberia TM Turkmenistan CV Cape Verde LS Lesotho TN Tunisia CY Cyprus LT Lithuania TO Tonga CODES FOR PUBLICATION IN BULLETIN CZ Czech Republic LU Luxembourg TR Turkey DE Germany LV Latvia SE Sweden (21) AP 0000 000000 _ serial number of application for invention DJ Djibouti LY Libyan Arab Jamahiriya TT Trinidad and Tobago INTERNATIONAL PATENT CLASSIFICATION (10) AP 0000 0000 A _ number of published application for invention (first publication) DM Dominica MA Morocco TV Tuvalu FOR INVENTIONS AND UTILITY MODELS (11) P 0000 0000 B _ number of patent for invention (second publication) DO Dominican Republic MC Monaco TW Taiwan, Province of China DZ Algeria MD Republic of Moldova TZ United Republic of Tanzania (21) API 0000 000000 _ number of application for imported patent SECTION A _ HUMAN NECESSITIES EA Eurasian Patent Organization (EAPO) ME Montenegro UA Ukraine (11) PI 0000 0000 A _ number of imported patent (first publication) SECTION B _ PERFORMING OPERATIONS; TRANSPORTING EC Ecuador MG Madagascar UG Uganda SECTION C _ CHEMISTRY; METALLURGY Estonia The former Yugoslav Republic of United States of America (21) AU 0000 000000 _ serial number of application for utility model EE MK US SECTION D _ TEXTILES; PAPER Egypt Macedonia Uruguay (10) AU 0000 000 U _ number of published application for utility model (first publication) EG UY SECTION E _ FIXED CONSTRUCTIONS Western Sahara Mali Uzbekistan (11) U 0000 000 Y _ number of patent for utility model (second publication) EH ML UZ SECTION F _ MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; EM Office
Load more

Recommended publications
  • Multi-Class Determination of 64 Illicit Compounds in Dietary Supplements Using Liquid Chromatography–Tandem Mass Spectrometry
    molecules Article Multi-Class Determination of 64 Illicit Compounds in Dietary Supplements Using Liquid Chromatography–Tandem Mass Spectrometry Dasom Shin, Hui-Seung Kang *, Hyungsoo Kim and Guiim Moon New Hazardous Substances Division, Department of Food Safety Evaluation, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Osong, Cheongju 28159, Korea; [email protected] (D.S.); [email protected] (H.K.); [email protected] (G.M.) * Correspondence: [email protected] Received: 11 August 2020; Accepted: 17 September 2020; Published: 24 September 2020 Abstract: In this work, liquid chromatography–tandem mass spectrometry (LC-MS/MS) method was developed and validated for screening and confirmation of 64 illicit compounds in dietary supplements. The target compounds were illegally used pharmaceutical drugs, prohibited compounds, and not authorized ingredients for different therapeutics (sexual enhancement, weight loss, muscular strengthening, and relaxing products). The validation procedure was performed to evaluate selectivity, linearity, limit of detection (LOD), limit of quantification (LOQ), accuracy, and precision according to the Association of Official Analytical Chemists guidelines. The linearity was >0.98 in the range of 1 1 0.5–200 µg L− . The LOQs were in the range 1–10 µg kg− for all target compounds. The accuracy (expressed as recovery) was 78.5–114%. The precision (expressed as the relative standard deviation) was below 9.15%. The developed method was applied for the determination of illicit compounds in dietary supplements collected from websites. As a result, the total detection rate was 13.5% (27 samples detected in 200 samples). The concentrations of detected samples ranged from 0.51 1 to 226 mg g− .
    [Show full text]
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]
  • Herbals, Complementary Medicines & Nutritional Supplements (PDF)
    Herbals, Complementary Medicines Nutritional & Supplements Complementary medicines and nutritional supplements are a popular addition to “traditional” medicine. Information about these therapies can range from news reports and magazine articles to advertising that may contain false claims. This pamphlet was designed to provide veterans and their families with unbiased information. The information in this pamphlet is not intended to take the place of advice from your healthcare provider. Angela Paniagua, Pharm.D., CGP Pharmacy Program, Clement J. Zablocki VAMC Milwaukee, WI Complementary medicines and nutritional supplements are not miracle cures. Do not stop taking your prescription medicine without speaking to your health care provider. Doing so may be dangerous to your health. Warning Several complementary medications have been found to be unsafe and/or unpure. All patients should avoid: 5-HTP DHEA Shark Cartilage Bee Venom L-tryptophan What is herbal therapy? Herbs have been used in medicine for as long as people have been on earth. The use of herbal therapies has been recorded in ancient Greece, Egypt, Rome, India, Russia, and China. Many modern medicines came from Native American remedies. There are many examples of drugs used today that are from plants. They may come from the plant's leaves, roots, flowers or fruits. Digoxin is a good example of a drug that comes from a plant source. Digoxin is used to treat problems with heart rhythms or heart failure. Psyllium, the ingredient in Metamucil© used to add fiber to a patient's diet, is also a natural product. Taxol®, made from a type of tree bark, is used to treat cancer.
    [Show full text]
  • PDF-Document
    Figure S1. Chromatogram of 66 compounds at 0.05 mg L-1 Figure S2. Example of chromatogram and mass spectra in sample (S-162, sennosides) Table S1. Selection criteria of 66 target compounds based on Korean legislation. Not Not Prohibited Prohibited Compounds Pharmaceutical authorized Compounds Pharmaceutical authorized compounds1) compounds1) ingredients2) ingredients2) 2,4-Dinitrophenol (2,4-DNP) Ο Liothyronine Ο Ο 7-keto-dehydroepiandrosterone (7-keto-DHEA) Ο Lorcaserine Ο Amphetamine Ο Lovastatin Ο Asarone Ο Magnoflorine Ο Atropine Ο Melatonin Ο Berberine Ο Metformin Ο beta-methylphenethylamine (BMPEA) Ο Methylclothiazide Ο Bisacodyl Ο Mexamine (5-methoxytryptamine) Ο Buformin Ο N-nitrosofenfluramine Ο Ο Cascaroside A Ο Ο Noopept Ο Cascaroside B Ο Ο Oxilofrine Ο Cascaroside C Ο Ο Oxindole Ο Cascaroside D Ο Ο Oxitriptan (5-hydroxytryptohpane) Ο Chlorothiazide Ο Phendimetrazine Ο Cimifugin Ο Phenformin Ο Dehydroepiandrosterone (DHEA) Ο Phenolphtalein Ο Ο Echinacoside Ο Phentermine Ο Ephedrine Ο Ο Picamilon Ο Fenfluramine Ο Ο Rauwolscine (α-yohimbine) Ο Ο Fluoxetine Ο Ο Reserpine Ο Glibenclamide Ο Ο Salbutamol Ο Gliclazide Ο Ο Salicin Ο Glimepiride Ο Ο Salicylic acid Ο Glipizide Ο Ο Scopolamine Ο Hesperidin Ο Sennoside A Ο Ο Hydrastine Ο Sennoside B Ο Ο Hydrochlorothiazide Ο Serotonin (5-hydroxytryptamine) Ο Hydroflumethiazide Ο Synephrine Ο Icariin Ο Ο Tolbutamide Ο Icaritin Ο Trichloromethiazide Ο Kavain Ο Trigonelline Ο Levodopa Ο Vinpocetine Ο Levothyroxine Ο Ο Yohimbine (β-yohimbine) Ο Ο 1) Prohibited by Food and Sanitation Act in Ministry of Food and Drug Safety in Korea 2) Not authorized food ingredients by Food Code in Korea Table S2.
    [Show full text]
  • Known Bioactive Library: Microsource 1 - US Drug Collection
    Known Bioactive Library: Microsource 1 - US Drug Collection ICCB-L ICCB-L Vendor Vendor Compound Name Bioactivity Source CAS Plate Well ID antifungal, inhibits Penicillium 2091 A03 Microsource 00200046 GRISEOFULVIN 126-07-8 mitosis in metaphase griseofulvum 3505-38-2, 486-16-8 2091 A04 Microsource 01500161 CARBINOXAMINE MALEATE antihistaminic synthetic [carbinoxamine] 2091 A05 Microsource 00200331 SALSALATE analgesic synthetic 552-94-3 muscle relaxant 2091 A06 Microsource 01500162 CARISOPRODOL synthetic 78-44-4 (skeletal) antineoplastic, 2091 A07 Microsource 00210369 GALLIC ACID insect galls 149-91-7 astringent, antibacterial 66592-87-8, 50370-12- 2091 A08 Microsource 01500163 CEFADROXIL antibacterial semisynthetic 2 [anhydrous], 119922- 89-9 [hemihydrate] Rheum palmatum, 2091 A09 Microsource 00211468 DANTHRON cathartic 117-10-2 Xyris semifuscata 27164-46-1, 25953-19- 2091 A10 Microsource 01500164 CEFAZOLIN SODIUM antibacterial semisynthetic 9 [cefazolin] glucocorticoid, 2091 A11 Microsource 00300024 HYDROCORTISONE adrenal glands 50-23-7 antiinflammatory 64485-93-4, 63527-52- 2091 A12 Microsource 01500165 CEFOTAXIME SODIUM antibacterial semisynthetic 6 [cefotaxime] 2091 A13 Microsource 00300029 DESOXYCORTICOSTERONE ACETATE mineralocorticoid adrenocortex 56-47-3 58-71-9, 153-61-7 2091 A14 Microsource 01500166 CEPHALOTHIN SODIUM antibacterial semisynthetic [cephalothin] 2091 A15 Microsource 00300034 TESTOSTERONE PROPIONATE androgen, antineoplastic semisynthetic 57-85-2 24356-60-3, 21593-23- 2091 A16 Microsource 01500167 CEPHAPIRIN SODIUM
    [Show full text]
  • Prospectives of Helicobacter Pylori
    Sys Rev Pharm 2021; 12(8): 460-465 Review Article A multifaceted review journal in the field of pharmacy E-ISSN 0976-2779 P-ISSN 0975-8453 Research Article Prospectives of Helicobacter pylori S Manodhini Elakkiya*, R Sambath Kumar, N Venkateswaramurthy Department of pharmaceutics, JKK Nattraja College of Pharmacy, Tamil Nadu, India Article History: Submitted: 26.04.2021 Accepted: 10.05.2021 Published: 17.05.2021 ABSTRACT creasing prevalence of resistant strains of H. pylori and achieve a >90% eradication rate. Although treatment Helicobacter pylori is a gram negative bacteria (H. pylori) regimens provide acceptable eradication rates, whose infection is highly prevalent among the human H. pylori the regimens used should contribute to future resis- population and leads to gastrointestinal tract related tance of diseases (gastric and duodenal ulcers, mucosa asso- H. pylori to antimicrobials and other therapies. ciated tissue lymphoma and gastric adenocarcinoma). infection will never have any Most people with H. pylori Keywords: Helicobacter pylori, Route of transmission, signs or symptoms. While this bacterium infects 50% Thumb rules, Treatment regimen of the world’s population, in Africa its prevalence reach as high as 80% as the infection is acquired during child- hood. H. pylori eradication treatment is becoming more *Correspondence: S Manodhini Elakkiya, Department challenging due to increasing antimicrobial resistance. of Pharmaceutics, JKK Nattraja College of Pharmacy, Treatment regimens are expected to overcome the in- Tamil Nadu, India, E-mail: [email protected] INTRODUCTION ents or siblings and they are also affected due to the transmission Helicobacter pylori (H. pylori), previously known as Campylo- of the bacterium to the GI tract by oral cavity, by fecal-oral route bacter pylori, are a spiral shaped bacteria which is indicated by or by human to human transmission (Zhao S, et al., 2014; Safavi the term ‘Helico’.
    [Show full text]
  • Hydrastis Canadensis) on BACTERIAL MULTI DRUG RESISTANT EFFLUX PUMPS Jyothi Rangineni Clemson University, [email protected]
    Clemson University TigerPrints All Dissertations Dissertations 8-2011 EFFECT OF GOLDENSEAL (Hydrastis canadensis) ON BACTERIAL MULTI DRUG RESISTANT EFFLUX PUMPS Jyothi Rangineni Clemson University, [email protected] Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations Part of the Microbiology Commons Recommended Citation Rangineni, Jyothi, "EFFECT OF GOLDENSEAL (Hydrastis canadensis) ON BACTERIAL MULTI DRUG RESISTANT EFFLUX PUMPS" (2011). All Dissertations. 785. https://tigerprints.clemson.edu/all_dissertations/785 This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been accepted for inclusion in All Dissertations by an authorized administrator of TigerPrints. For more information, please contact [email protected]. EFFECT OF GOLDENSEAL (Hydrastis canadensis) ON BACTERIAL MULTI DRUG RESISTANT EFFLUX PUMPS A Dissertation Presented to the Graduate School of Clemson University In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy Microbiology by Jyothi Rangineni December 2009 Accepted by: Dr. Tzuen-Rong Tzeng, Committee Chair Dr. Joseph Gangemi Dr. Xiuping Jiang Dr. Melissa Riley Abstract Multi-Drug-Resistance (MDR) efflux pumps have been increasingly reported in Gram negative and Gram positive bacteria. These efflux mechanisms pump out a wide variety of structurally unrelated antimicrobials thus leading to reduced susceptibility due to lowered intracellular concentrations. The activity of such antimicrobials can be restored by the inhibition of the multi-drug efflux pumps. Several MDR pump inhibitors which inhibit the efflux mechanisms in bacteria have been identified. Reserpine and verapamil are two such inhibitors showing considerable effects on the MDR pumps. But the concentrations required to achieve these effects are too high to be clinically relevant.
    [Show full text]
  • ACMT 2020 Annual Scientific Meeting Abstracts – New York, NY
    Journal of Medical Toxicology https://doi.org/10.1007/s13181-020-00759-7 ANNUAL MEETING ABSTRACTS ACMT 2020 Annual Scientific Meeting Abstracts – New York, NY Abstract: These are the abstracts of the 2020 American College of Background: Oral cyanide is a potentially deadly poison and has the Medical Toxicology (ACMT) Annual Scientific Meeting. Included here potential for use by terrorists. There is potential for a mass casualty ex- are 174 abstracts that will be presented in March 2020, including research posure scenario, and currently, there are no FDA-approved antidotes spe- studies from around the globe and the ToxIC collaboration, clinically cifically for oral cyanide poisoning. significant case reports describing new toxicologic phenomena, and en- Hypothesis: We hypothesize that animals treated with oral sodium thio- core research presentations from other scientific meetings. sulfate will have a higher rate of survival vs. control in a large animal model of acute, severe, oral cyanide toxicity. Keywords Abstracts, Annual Scientific Meeting, Toxicology Methods: This is a prospective study that took place at the University of Investigators Consortium, Medical Toxicology Foundation Colorado Anschutz Medical Campus. Nine swine (45–55 kg) were in- strumented, sedated, and stabilized. Potassium cyanide (8 mg/kg KCN) in Correspondence: American College of Medical Toxicology (ACMT), saline was delivered as a one-time bolus via an orogastric tube. Three 10645 N. Tatum Blvd, Phoenix, AZ, USA; [email protected] minutes after cyanide, animals who were randomized to the treatment group received sodium thiosulfate (508.2 mg/kg, 3.25 M solution) via Introduction: The American College of Medical Toxicology (ACMT) re- orogastric tube.
    [Show full text]
  • Review on Plant Antimicrobials: a Mechanistic Viewpoint Bahman Khameneh1, Milad Iranshahy2,3, Vahid Soheili1 and Bibi Sedigheh Fazly Bazzaz3*
    Khameneh et al. Antimicrobial Resistance and Infection Control (2019) 8:118 https://doi.org/10.1186/s13756-019-0559-6 REVIEW Open Access Review on plant antimicrobials: a mechanistic viewpoint Bahman Khameneh1, Milad Iranshahy2,3, Vahid Soheili1 and Bibi Sedigheh Fazly Bazzaz3* Abstract Microbial resistance to classical antibiotics and its rapid progression have raised serious concern in the treatment of infectious diseases. Recently, many studies have been directed towards finding promising solutions to overcome these problems. Phytochemicals have exerted potential antibacterial activities against sensitive and resistant pathogens via different mechanisms of action. In this review, we have summarized the main antibiotic resistance mechanisms of bacteria and also discussed how phytochemicals belonging to different chemical classes could reverse the antibiotic resistance. Next to containing direct antimicrobial activities, some of them have exerted in vitro synergistic effects when being combined with conventional antibiotics. Considering these facts, it could be stated that phytochemicals represent a valuable source of bioactive compounds with potent antimicrobial activities. Keywords: Antibiotic-resistant, Antimicrobial activity, Combination therapy, Mechanism of action, Natural products, Phytochemicals Introduction bacteria [10, 12–14]. However, up to this date, the Today’s, microbial infections, resistance to antibiotic structure-activity relationships and mechanisms of action drugs, have been the biggest challenges, which threaten of natural compounds have largely remained elusive. In the health of societies. Microbial infections are responsible the present review, we have focused on describing the re- for millions of deaths every year worldwide. In 2013, 9.2 lationship between the structure of natural compounds million deaths have been reported because of infections and their possible mechanism of action.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Tinnitus
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Tinnitus Chemical Activity Count (+)-ALPHA-VINIFERIN 1 (+)-AROMOLINE 1 (+)-BORNYL-ISOVALERATE 1 (+)-CATECHIN 1 (+)-EUDESMA-4(14),7(11)-DIENE-3-ONE 1 (+)-HERNANDEZINE 2 (+)-ISOLARICIRESINOL 1 (+)-NORTRACHELOGENIN 1 (+)-PSEUDOEPHEDRINE 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 1 (+)-T-CADINOL 1 (-)-16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 (-)-ALPHA-BISABOLOL 1 (-)-ANABASINE 1 (-)-APOGLAZIOVINE 1 (-)-BETONICINE 1 (-)-BORNYL-CAFFEATE 1 (-)-BORNYL-FERULATE 1 (-)-BORNYL-P-COUMARATE 1 (-)-CANADINE 1 (-)-DICENTRINE 1 (-)-EPICATECHIN 2 (-)-EPIGALLOCATECHIN-GALLATE 1 (1'S)-1'-ACETOXYCHAVICOL-ACETATE 1 (E)-4-(3',4'-DIMETHOXYPHENYL)-BUT-3-EN-OL 1 1,7-BIS-(4-HYDROXYPHENYL)-1,4,6-HEPTATRIEN-3-ONE 1 1,8-CINEOLE 4 Chemical Activity Count 1-ETHYL-BETA-CARBOLINE 2 10-ACETOXY-8-HYDROXY-9-ISOBUTYLOXY-6-METHOXYTHYMOL 1 10-DEHYDROGINGERDIONE 1 10-GINGERDIONE 1 12-(4'-METHOXYPHENYL)-DAURICINE 1 12-METHOXYDIHYDROCOSTULONIDE 1 13',II8-BIAPIGENIN 1 13-HYDROXYLUPANINE 1 13-OXYINGENOL-ESTER 1 16,17-DIHYDROXY-16BETA-KAURAN-19-OIC 1 16-HYDROXY-4,4,10,13-TETRAMETHYL-17-(4-METHYL-PENTYL)-HEXADECAHYDRO- 1 CYCLOPENTA[A]PHENANTHREN-3-ONE 16-HYDROXYINGENOL-ESTER 1 2'-O-GLYCOSYLVITEXIN 1 2-BETA,3BETA-27-TRIHYDROXYOLEAN-12-ENE-23,28-DICARBOXYLIC-ACID 1 2-METHYLBUT-3-ENE-2-OL 2 2-VINYL-4H-1,3-DITHIIN 1 20-DEOXYINGENOL-ESTER 1 22BETA-ESCIN 1 24-METHYLENE-CYCLOARTANOL 2 3,3'-DIMETHYLELLAGIC-ACID 1 3,4-DIMETHOXYTOLUENE 2 3,4-METHYLENE-DIOXYCINNAMIC-ACID-BORNYL-ESTER 1 3,4-SECOTRITERPENE-ACID-20-EPI-KOETJAPIC-ACID
    [Show full text]